Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-21-013100
Date:2021-02-19
Issuer: ULTRAGENYX PHARMACEUTICAL INC. (RARE)
Original Submission Date:

Reporting Person:

ALISKI WILLIAM
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT NOVATO, CA 94949

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-02-19 M 7,500 a $97.85 73,204 direct
COMMON STOCK 2021-02-19 S 7,500 d $149.01 65,704 direct
COMMON STOCK 2021-02-23 G 1,000 d $0.00 64,704 direct
COMMON STOCK 0 $0.00 70,350 indirect f3
COMMON STOCK 0 $0.00 10,456 indirect f4
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 97.85 2021-02-19 deemed execution date M 7,500 (d) 2025-06-18 common stock 7,500 $97.85 0 direct
Footnotes
IDfootnote
f1 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $149.00 to $149.15 inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range.
f2 includes previously reported shares of common stock underlying rsus granted to the reporting person, which are subject to certain vesting conditions.
f3 these shares are held in a trust for the benefit of the reporting person's spouse and children. the reporting person's spouse and nephew are trustees of the trust.
f4 these shares are held in a grantor retained annuity trust. the reporting person is the trustee of the trusts.
f5 the option vested in full on on june 9, 2016.

Elevate your investments